St. Jude Defibrillator Battery Failure Recall Updated To Announce New Battery Monitoring Software

As individuals continue to deal with the consequences of a St. Jude defibrillator battery recall issued last year, federal regulators are notifying doctors that there is a new tool available to help predict battery failure for the implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). 

Last week, the FDA announced an update to the St. Jude ICD and CRT-D recall originally issued on October 20, 2016. New information has been provided about a “St. Jude’s Battery Performance Alert (BPA)”, which is a management tool designed to provide earlier detection of imminent battery failure for the implanted heart devices.

The battery problems have plagued certain St. Jude Fortify, Unify and Assura defibrillators, which could experience rapid battery failure. At least two deaths and dozens of adverse events have been linked to the issue.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Additionally, the agency issued a warning letter to St. Jude in April, indicating that investigators have discovered that at least 10 recalled defibrillators were shipped out after the problem was identified, and seven had been implanted in unsuspecting patients.

St. Jude issued a Dear Doctor letter (PDF) in late August, announcing the BPA software. The new software was sent out through the company’s Merlin.net wireless network to upgrade patients’ remote monitoring systems.

According to St. Jude, the software uses an algorithm that can detect abnormal battery performance before the batteries fail. If the alert is triggered, the company recommends the device immediately be removed and replaced.

“Battery information is uploaded automatically each night to Merlin.net where the most recent 32 days of data are analyzed each day to determine if an anomalous battery voltage trend is observed,” St. Jude wrote to its customers. “Once the BPA is triggered, notification is provided to physicians through the Merlin.net monitoring system and the Merlin programmer during routine follow-up evaluations. For patients not followed remotely with Merlin.net, the status of their battery and whether the BPA has triggered an alert can only be determined with in-person interrogation using the Merlin programmer.”

A number of lawsuits over St. Jude defibrillator battery problems have been filed, including class action claims on behalf of insurers who covered the cost of buying and replacing the devices, as well as individual injury cases.

Plaintiffs allege that St. Jude knew about the potential risk of defibrillator battery problems as early as 2011, but continued to distribute implants they knew could fail prematurely, without disclosing the risks.

St. Jude has said that it was unable to confirm the problem until the recall was announced last year. Consumers and doctors with questions regarding the recall, monitoring and the new software can contact a local sales representative or call Abbott Technical Services at 1-800-722-3774.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades
Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades (Posted today)

After decades of medical research and reported Depo-Provera side effects, Pfizer should have known that its birth control shot increases the risks of meningioma brain tumors, yet failed to warn women or the medical community.

Philadelphia Roundup Lawsuit Ends in Defense Verdict for Monsanto
Philadelphia Roundup Lawsuit Ends in Defense Verdict for Monsanto (Posted yesterday)

Bayer and Monsanto prevailed in a Roundup lawsuit that went to trial in Philadelphia this week, after a jury found that exposure to the herbicide did not cause a man to develop non-Hodgkin's lymphoma.

Family Seeks Remand of Bard Hernia Mesh Wrongful Death Lawsuit, After Global Settlement Negotiations “Have Dragged”
Family Seeks Remand of Bard Hernia Mesh Wrongful Death Lawsuit, After Global Settlement Negotiations “Have Dragged” (Posted yesterday)

The Bard hernia mesh lawsuit has been pending for years in the federal MDL, where family indicates global settlement negotiations have stalled, leading to a request to allow their claim to be remanded for trial.